Bulletins

Engineered Nipah virus glycoproteins pseudotyped onto lentiviral vectors enable highly selective and efficient gene delivery. These vectors achieve up to 10–100-fold higher titers than measles-based systems, resist antibody neutralization, and preferentially target membrane-proximal receptors, significantly enhancing transduction efficiency and demonstrating strong potential for targeted gene therapy applications.

Study found that postnatal depression among women increase risk of their children not performing well academically by 1.5 times. Maternal depression after delivery affects child’s attention by 16% while maternal anxiety during pregnancy affects the cognitive memory of the child by 17%.

NanoLuc technology developed using a split NanoLuc biosensor, enables simple mix-and-read detection of Nipah virus antibodies. The biosensor is 98.6 sensitive and 100% specific for detecting IgG antibodies in Nipah virus infected patients. The NanoLuc Biosensor thus offers a fast, sensitive, and scalable approach for serological surveillance and retrospective analysis of the deadliest viral infections

Scientist have identified the VV116 as a drug to control growth of Nipah virus and prevent development of acute encephalitis. At an effective dose of 400mg/kg in humans, the virus demonstrated favourable pharmacokinetics, minimal tissue damage and improved survival rates of 67%, VV116 is suggested as an effective oral therapeutic candidate against Nipah virus.